Key facts
- It has raised $50K; the latest was Angel (individual) ($50K) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Scudo Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Scudo Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scudo Biosciences
Developer of a biotechnology platform designed to enhance immune resilience and cellular protection. The company focuses on transforming patient outcomes by minimizing immunosuppression and advancing safer, more effective treatments, helping clients in pioneering immune shields for cell and gene therapy.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Website
- scudo.bio/
- Ownership
- Privately Held (backing)
Scudo Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scudo Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scudo Biosciences in its N-PORT filings yet. We sweep new filings monthly.